In their recent commentary on cancer care outcomes research, Ayanian et al1 reflect the broader concern of the oncology community to understand better how to optimize cancer treatment andoutcomes inways that are appropriate to the racial, ethnic, age, and socioeconomic diversity of cancer experiences. Moreover, understanding the diversity of experiences with cancer adds to our broader comprehen-sion of cancer treatment and outcomes themselves, and provides opportunities to develop more sophisticated the-oretical and treatment models for all people. From preven-tion to treatment options to health-related quality of life and long-term survivorship, diversity clearly matters but is inadequately reflected in cancer research and practice. Yet, d...
Background: Cancer and its treatments can significantly impact on a person’s sexuality and intimacy,...
Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of canc...
Prostate cancer (CaP) is the most diagnosed non-cutaneous malignancy and the second leading cause of...
All progress is precarious, and the solution of one problem brings us face to face with another prob...
Objectives: To summarise black and minority ethnic (BME) patients' and partners experiences of prost...
Research conducted with prostate cancer (PC) survivors has previously noted ethnic disparities in kn...
As researchers recognize the value in considering gender dynamics within the cancer experience, a ma...
There is convincing documentation of racial variation in the incidence and mortality of many cancers...
Disparities in cancer are common among the racial and ethnical minorities in the United States and a...
Purpose Men diagnosed with prostate cancer have multiple options available for treatment. Previous r...
OBJECTIVE: We examined whether there were racial differences in initial treatment for clinically loc...
Information and understanding are needed so that men with prostate cancer can effectively manage and...
A key element of the mission of the Sidney Kimmel Cancer Center–Jefferson Health—and an objective of...
The importance of couplehood in the context of cancer has been highlighted in recent national debate...
have earlier onset of prostate cancer, higher prostate-specific antigen (PSA) levels, more advanced ...
Background: Cancer and its treatments can significantly impact on a person’s sexuality and intimacy,...
Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of canc...
Prostate cancer (CaP) is the most diagnosed non-cutaneous malignancy and the second leading cause of...
All progress is precarious, and the solution of one problem brings us face to face with another prob...
Objectives: To summarise black and minority ethnic (BME) patients' and partners experiences of prost...
Research conducted with prostate cancer (PC) survivors has previously noted ethnic disparities in kn...
As researchers recognize the value in considering gender dynamics within the cancer experience, a ma...
There is convincing documentation of racial variation in the incidence and mortality of many cancers...
Disparities in cancer are common among the racial and ethnical minorities in the United States and a...
Purpose Men diagnosed with prostate cancer have multiple options available for treatment. Previous r...
OBJECTIVE: We examined whether there were racial differences in initial treatment for clinically loc...
Information and understanding are needed so that men with prostate cancer can effectively manage and...
A key element of the mission of the Sidney Kimmel Cancer Center–Jefferson Health—and an objective of...
The importance of couplehood in the context of cancer has been highlighted in recent national debate...
have earlier onset of prostate cancer, higher prostate-specific antigen (PSA) levels, more advanced ...
Background: Cancer and its treatments can significantly impact on a person’s sexuality and intimacy,...
Prostate cancer (PCa) is the most commonly diagnosed malignancy and the second leading cause of canc...
Prostate cancer (CaP) is the most diagnosed non-cutaneous malignancy and the second leading cause of...